Cite
HARVARD Citation
Kim, T. et al. (2021). Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea. Cancer medicine. pp. 5809-5822. [Online].